Combo Tx Promising in Non-Clear Cell Renal Carcinoma (CME/CE)

(MedPage Today) -- 'Compelling' results from Zortress-Avastin phase II trial
via Combo Tx Promising in Non-Clear Cell Renal Carcinoma (CME/CE)
by